Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 321

1.

Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].

Kulasingam SL, Havrilesky L, Ghebre R, Myers ER.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May.

2.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

3.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

4.

Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.

Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U.

GMS Health Technol Assess. 2010 Apr 27;6:Doc05. doi: 10.3205/hta000083.

5.
6.

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ.

J Natl Cancer Inst. 2008 Mar 5;100(5):308-20. doi: 10.1093/jnci/djn019. Epub 2008 Feb 26.

7.

Fluorescence In Situ Hybridization (FISH) or Other In Situ Hybridization (ISH) Testing of Uterine Cervical Cells to Predict Precancer and Cancer [Internet].

Uhlig K, Earley A, Lamont J, Dahabreh IJ, Avendano EE, Cowan JM, Feldman S.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Feb 16.

8.

Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.

Simms KT, Hall M, Smith MA, Lew JB, Hughes S, Yuill S, Hammond I, Saville M, Canfell K.

PLoS One. 2017 Jan 17;12(1):e0163509. doi: 10.1371/journal.pone.0163509. eCollection 2017.

9.

[Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].

Ronco G, Confortini M, Maccallini V, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Giorgi Rossi P.

Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 2):e1-e33. Review. Italian.

10.
11.

Screening for cervical cancer: a modeling study for the US Preventive Services Task Force.

Kulasingam SL, Havrilesky LJ, Ghebre R, Myers ER.

J Low Genit Tract Dis. 2013 Apr;17(2):193-202. doi: 10.1097/LGT.0b013e3182616241.

12.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
13.

Trade-offs in cervical cancer prevention: balancing benefits and risks.

Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ.

Arch Intern Med. 2008 Sep 22;168(17):1881-9. doi: 10.1001/archinte.168.17.1881.

14.

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.

Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.

PMID:
23199969
15.

Anal dysplasia screening: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2007;7(4):1-43. Epub 2007 Jun 1.

16.

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N; New Technologies for Cervical Cancer Screening Working Group..

J Natl Cancer Inst. 2008 Apr 2;100(7):492-501. doi: 10.1093/jnci/djn065. Epub 2008 Mar 25.

PMID:
18364502
17.

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

Kim JJ, Wright TC, Goldie SJ.

J Natl Cancer Inst. 2005 Jun 15;97(12):888-95.

PMID:
15956650
18.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
19.

Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.

Del Mistro A, Frayle H, Ferro A, Callegaro S, Del Sole A, Stomeo A, Cirillo E, Fedato C, Pagni S, Barzon L, Zorzi M; Veneto HPV-screening Working Group..

J Med Screen. 2014 Mar;21(1):30-7. doi: 10.1177/0969141314522219. Epub 2014 Jan 31.

PMID:
24488593
20.

[Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].

Della Palma P, Moresco L, Giorgi Rossi P.

Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 3):e1-43. Italian.

Supplemental Content

Support Center